Product Name: CDK2 Antibody, Monoclonal
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, IF, IHC, IP, WB
Applications: CDK2 antibody can be used in immunohistochemistry starting at 2.5 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: CDK2 monoclonal antibody was raised against recombinant CDK2 (Human).
Host Species: Mouse
Purification: Protein A Column
Physical State: Liquid
CAS NO.: 121123-17-9
Product: Cefprozil (monohydrate)
Buffer: 10mM PBS, pH 7.4, 0.2% BSA, 0.09% sodium azide, before the addition of glycerol to 40%
Concentration:
Storage Conditions: Store CDK2 antibody at 4 ˚C or -20 ˚C. As with all antibodies avoid freeze/thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: CDK2, CDC2, Cell devision kinase 2, Cell division protein kinase 2, CDC2-related protein kinase, Cell division kinase 2, p33 protein kinase, p33(CDK2), CDKN2, Cyclin-dependent kinase 2
Accession NO.: P24941
Protein Ino: 116051
Official Symbol: CDK2
Geneid: 1017
Background: p33cdk2 associates with cyclin A in human cells. Kinase activity associated with cyclin A-cdc2 is found only in G2-phase. Cdk2 also complexes with cyclins E, D1, and D3. Cyclin Ecdk2 kinase is active in the G1- and S-phases of the cell cycle and is important (as does cyclin A-cdk2) for the progression from G1-to S-phase. The levels of cyclin A-cdk2 is maximal at the G1/S transition and both cdk2 and cyclin A are found associated with DNA in the initiation complex during replication. Rb protein acts as substrate for cdk2-cyclin E and/or cdk2-cyclin A in vivo. Cdk2 is activated and specifically localized to the nucleus during late G1-, S-, and G2-phase. Immunofluorescence Immunoprecipitation (Denatured only) (Use Protein A) (Ab 2ug/mg protein lysate) Western Blot (Ab 1-2 μg/mL for 2hrs at RT) Positive Control HeLa cells Cellular Localization Cytoplasmic and nuclear Recognizes Cdk2. Species Crossreactivity: Human, Mouse, and Rat.Cyclin-dependent kinase 2 (CDK2), a CDC2/CDK-type protein kinase, regulates cell-cycle transition from G1 to S phase. CDK2 activation requires formation of a heterodimer with cyclin A, D, or E and phosphorylation by CAK. CDK2 inhibition results from association with p21Cip1 (CDKN1A) and p27Kip1 (CDKN1B). Two alternatively spliced variants and multiple transcription initiation sites have been reported. Inhibition of CDK2 has been suggested to help prevent chemotherapy-induced alopecia in cancer patients.
PubMed ID:http://aac.asm.org/content/35/8/1666.abstract
